Results 71 to 80 of about 212,093 (280)
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
Is Taking a Pill a Day Good for Health Expenditures? Evidence from a Cross Section Time Series Analysis of 19 OECD Countries from 1970 – 2000 [PDF]
This paper differs in two ways from previous comparative health system research. First, it focuses on the impact of pharmaceutical expenditures on total health expenditures as trends in pharmaceutical expenditures have been blamed of being a major driver
Verbelen, Bart
core
Innovation and corporate dynamics: a theoretical framework [PDF]
, 2011 We provide a detailed analysis of a generalized proportional growth model (GPGM) of innovation and corporate dynamics that encompasses the Gibrat’s Law of Proportionate Effect and the Simon growth process as particular instances.
Growiec, Jakub +2 more
core
British Journal of Clinical Pharmacology, EarlyView.Feedback is the most powerful driver of learning, but it can afford variable effects depending on the method used. The design of feedback for computer‐based assessment—now increasingly prevalent in higher education—remains relatively underexplored, particularly for pharmacology education.
Claire Y. Hepburn
wiley +1 more source
The simple economics of risk-sharing agreements between the NHS and the pharmaceutical industry [PDF]
The Janssen-Cilag proposal for a risk-sharing agreement regarding bortezomib received a welcome signal from NICE. The Office of Fair Trading report included risk-sharing agreements as an available tool for the National Health Service. Nonetheless, recent
Barros, Pedro Pita
core +1 more source
Designing the Business Model of Herbal Pharmaceutical Knowledge based Companies [PDF]
, 2017 Today, research has indicated Knowledge based companies as a potential area in promoting knowledge economy, and due to the substantial added-value they make in the knowledge economy of the countries, these companies play a pivotal role in producing ...
Akbari, Morteza +3 more
core +1 more source
Integrated Pharmacy Research and Practice, 2020 Maria Kamusheva, 1 Desislava Ignatova, 2 Anna Golda, 3 Agnieszka Skowron 3 1Department of “Organization and Economics of Pharmacy”, Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria; 2Department of “Psychiatry and ...
Kamusheva M +3 more
doaj
POTENTIALS OF INTERACTIVE TEACHING TECHNIQUES TO TRAIN EXPERTS IN PHARMACY
Фармация и фармакология (Пятигорск), 2016 Various interactive teaching methods and techniques are extensively used in modern higher schools. Their implementation is considered to be one of the most significant and efficient ways to improve quality of pharmaceutical professional training ...
A. V. Krikova +4 more
doaj +1 more source
An inventive step for the patent system? [PDF]
, 2020 The inventive step is the critical variable in determining balance between patent costs and patent benefits. Set at the right level it ensures that the knowledge spillovers from new inventions offset the costs of restraining competition.
Moir, Hazel V J
core
British Journal of Clinical Pharmacology, EarlyView.Abstract This study investigated the attitudes and beliefs of older adults towards deprescribing statins in Australia, the United Kingdom and the United States, using an online, vignette‐based study. Presented with a hypothetical scenario in which a general practitioner advised stopping simvastatin, participants rated their level of agreement and ...
Sarah E. Vordenberg +5 more
wiley +1 more source